Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases
#Precigen to showcase rapid commercialization momentum and growing market adoption of first-and-only FDA-approved therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference.
View press release: bit.ly/jpm26-momentum#JPM26#JPM2026
#Precigen to participate in upcoming virtual fireside chats hosted by Cantor and H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with RRP. View event details: bit.ly/41VSmMT
Join us on Wednesday, September 18 for a fireside chat with @Precigen's President and CEO, Helen Sabzevari, at the 2024 Cantor Global Healthcare Conference. View details and register for the webcast: bit.ly/3LqNK9i#CantorHCC
@Precigen reports second quarter / first half 2024 financial results and business updates. View press release and join our conference call today at 4:30pm ET: bit.ly/3yGJAae$PGEN
